Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIDENT-3: repotrectinib versus crizotinib in TKI-naive ROS1-positive advanced NSCLC
NL-OMON59941Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Repotrectinib with Crizotinib (2 arms). Primary endpoint: Progression-free survival per BICR. Started May 2025; status: completed.
02
Drugs
repotrectinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59941.